Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
Frontiers in Pharmacology · 17.07.2023 · 14
DOI: 10.3389/fphar.2023.1217306 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.07.2023. Verfasst von Liang Tian und 15 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Proton pump inhibitors (PPIs) are the most used acid-inhibitory drugs, with a wide range of applications in the treatment of various digestive diseases. However, recently, there has been a growing number of digestive complications linked to PPIs, and several studies have indicated that the intestinal flora play an important role in these complications. Therefore, developing a greater understanding of the role of the gut microbiota in PPI-related digestive diseases is essential. Here, we summarize the current research on the correlation between PPI-related digestive disorders and intestinal flora and establish the altered strains and possible pathogenic mechanisms of the different diseases. We aimed to provide a theoretical basis and reference for the future treatment and prevention of PPI-related digestive complications based on the regulation of the intestinal microbiota.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
- Clinical Research Center, Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.
- Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Zitieren
APA
Tian, L., Huang, C., Fu, W., Gao, L., Mi, N., Bai, M., Ma, H., Zhang, C., Lu, Y., Zhao, J., Zhang, X., Jiang, N., Lin, Y., Yue, P., Yuan, J., & Meng, W. (2023). Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1217306
Vancouver
Tian L, Huang C, Fu W, Gao L, Mi N, Bai M, et al. Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1217306
BibTeX
@article{Tian2023,
author = {Tian, Liang and Huang, Chongfei and Fu, Wenkang and Gao, Long and Mi, Ningning and Bai, Mingzhen and Ma, Haidong and Zhang, Chao and Lu, Yawen and Zhao, Jinyu and Zhang, Xianzhuo and Jiang, Ningzu and Lin, Yanyan and Yue, Ping and Yuan, Jinqiu and Meng, Wenbo},
title = {Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1217306}
}
EUVIMED